Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $13.50 Consensus Target Price from Analysts

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $13.50.

A number of research analysts recently weighed in on ALLO shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Tuesday, March 19th. Finally, JPMorgan Chase & Co. decreased their price objective on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 27th.

Institutional Investors Weigh In On Allogene Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in Allogene Therapeutics in the first quarter valued at $78,000. Susquehanna Fundamental Investments LLC purchased a new stake in Allogene Therapeutics in the 1st quarter valued at about $1,280,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Allogene Therapeutics by 85.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 361,913 shares of the company’s stock valued at $1,768,000 after buying an additional 166,433 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Allogene Therapeutics by 66.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 32,348 shares of the company’s stock worth $145,000 after buying an additional 12,881 shares during the period. Finally, Bourgeon Capital Management LLC boosted its stake in Allogene Therapeutics by 12.8% during the first quarter. Bourgeon Capital Management LLC now owns 57,200 shares of the company’s stock worth $256,000 after buying an additional 6,500 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $2.86 on Tuesday. The stock has a market capitalization of $488.26 million, a PE ratio of -1.37 and a beta of 0.90. The business has a 50 day simple moving average of $3.99 and a 200-day simple moving average of $3.53. Allogene Therapeutics has a 12 month low of $2.23 and a 12 month high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.04. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative return on equity of 53.76%. On average, equities research analysts anticipate that Allogene Therapeutics will post -1.69 EPS for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).